NovaGo Therapeutics cierra una ronda de financiación para un estudio en lesiones agudas de la médula espinal

Positive

AI Analysis

Summary

NovaGo Therapeutics closed a $30 million Series B funding round led by Neurimmune and Pureos to advance a proof-of-concept study in acute spinal cord injuries.

Clinical Trial Data

Phase

proof of concept

Importance:6/10

Sentiment:

0.70

fundingSeries Bspinal cord injuryclinical trialcapital raise

Read the original article

Published by PR Newswire Biotech on September 2, 2026 10:00 AM

Read Original